

Anti-CD30 Antibody (Brentuximab Biosimilar)

Cat. No. AB117


Description	
Reactivities	Human/Cynomolgus
Target	CD30
Isotype	Human IgG1-Kappa
Conjugation	Unconjugated
ExpressSystem	HEK293
Applications	ELISA
MolecularWeight	49.1 kDa and 23.7 kDa.
Recommended Dilution Buffer	PBS (pH 7.4), contains no stabilizers or preservatives.
Purification	protein A
Sterility	0.2 µM filtered
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage	
Formulation	PBS, 10% glycerol (pH 7.4)
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background	
The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs).	

Assay Data


Bis-Tris PAGE



Brentuximab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data




The purity of Brentuximab Biosimilar is greater than 95% as determined by SEC-HPLC.

Assay Data

ELISA Data

Brentuximab Biosimilar ELISA
0.05µg Human CD30, His Tag Per Well



Immobilized Human CD30, His Tag at 0.5µg/ml (100µl/well) on the plate. Dose response curve for Brentuximab Biosimilar with the EC50 of 2.8ng/ml determined by ELISA.